Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients
Zanforlini BM, Ceolin C, Trevisan C, Alessi A, Seccia DM, Noale M, Maggi S, Guarnieri G, Vianello A, Sergi G
Aging clinical and experimental research · 26 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Università degli Studi di Padova
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2021-07-14 · Aging Clin Exp Res · vol. 34 · issue 1 · pp. 167–174
- Publisher
- Springer Science+Business Media
- Cited
- 34 citations · more than 88% of similar papers · 2.4× the field average
- References
- 35 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Magnesium in Health and Disease · Chronic Obstructive Pulmonary Disease (COPD) Research · Cystic Fibrosis Research Advances
- Keywords
- Medicine, COPD, Placebo, Spirometry, Quality of life (healthcare), Physical therapy, Randomized controlled trial, Internal medicine, Volunteer, Clinical trial
- MeSH
- humans, pulmonary disease, chronic obstructive, disease progression, magnesium, hand strength, quality of life, dietary supplements, aged
10 authors
From IT
- Bruno Micael ZanforliniUniversity of Padua
- Chiara Ceolin · correspondingUniversity of Padua
- Caterina TrevisanUniversity of Padua
- Agnese AlessiUniversity of Padua
- Daniele Michele SecciaUniversity of Padua
- Marianna NoaleNeuroscience Institute; National Research Council
Abstract
Background and aims
COPD is a common chronic condition in older age that impacts on daily activities and quality of life. Previous studies suggest that magnesium deficit in COPD patients affects bronco-obstruction, inflammation, and physical performance. We investigated whether oral magnesium supplementation in stable-phase COPD patients improves lung function, physical performance, and quality of life.
Methods
We conducted a double-blind randomized-controlled clinical study with 49 participants divided into two groups: one given 300 mg/day of magnesium citrate (n = 25) and the other one sachet/day of a placebo (n = 24). The following parameters were assessed at baseline and after 3 and 6 months: lung function (spirometry), physical performance (handgrip strength, lower limb strength, six-minute walk test), inflammation (e.g., C-reactive protein, CRP), disease-related symptoms, and quality of life (St George's Respiratory Questionnaire, EuroQoL-5D, the Modified British Medical Research Council Questionnaire).
Results
Linear mixed models revealed significantly lower CRP values in the intervention group than in the placebo group at the 6 month follow-up (β = - 3.2, 95% CI - 6.0, - 0.4, p = 0.03). Moreover, the maximum work for flexion tended to increase in both groups between the 3 and the 6 month assessments, especially in the placebo group. No significant differences within and between groups over the study period were observed for the other parameters tested.
Conclusions
Although the established minimum sample size was not reached, our results suggests that oral magnesium supplementation may have a potential anti-inflammatory role. On the other hand, it does not seem to substantially influence lung function, physical performance, and quality of life in COPD patients.
Trial registration
The study is registered in clinicaltrial.gov (Trial Registration: NCT02680769, 13 June 2016, retrospectively registered).
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.